Yoshiyama Annie, SVP of Finance at Allogene Therapeutics ($ALLO), sold shares on the open market twice in the last year for a total of about $21,000. Her most recent sale occurred on February 2, 2026. These sales rank her 11,017th among nearly 12,000 insiders by value sold, well below the average of $8.6 million across 6.4 transactions per insider. She made no open market purchases in the period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Yoshiyama Annie | SVP, Finance | S | Common Stock | 4167 | $1.72 | 130,322.0000 | 224,730,144 | 3.10% | 0.00% |
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Yoshiyama Annie | SVP, Finance | A | Stock Option (Right to buy) | 179691 | $0.00 | 179,691.0000 | 224,730,144 | 9999.99% | 0.08% |
| Feb. 2, 2026 | Allogene Therapeutics, Inc. | $ALLO | Yoshiyama Annie | SVP, Finance | A | Restricted Stock Unit | 50827 | $0.00 | 50,827.0000 | 224,730,144 | 9999.99% | 0.02% |
| April 21, 2025 | Allogene Therapeutics, Inc. | $ALLO | Yoshiyama Annie | SVP, Finance | S | Common Stock | 9601 | $1.41 | 130,663.0000 | 217,264,738 | 6.84% | 0.00% |
| Jan. 24, 2025 | Allogene Therapeutics, Inc. | $ALLO | Yoshiyama Annie | SVP, Finance | A | Common Stock | 36232 | $0.00 | 137,990.0000 | 0 | 35.61% | 0.00% |
| Jan. 24, 2025 | Allogene Therapeutics, Inc. | $ALLO | Yoshiyama Annie | SVP, Finance | A | Stock Option (Right to buy) | 128093 | $0.00 | 128,093.0000 | 0 | 9999.99% | 0.00% |